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ABSTRACT 
 
Background: The goal of the treatment of acute myocardial infarction (AMI) is to achieve a prompt 
and sustained reperfusion of the epicardial vessel. Primary percutaneous coronary angioplasty is by 
far the treatment of choice over thrombolysis. However, it fails to restore an adequate tissue 
perfusion in 25-30% of patients, despite Thrombolysis In Myocardial Infarction (TIMI) grade 3 
flow. Inadequte tissue perfusion is associated with left ventricular remodeling, thus negatively 
affecting patient prognosis. 
Aim: to investigate angiographic predictors of left ventricualr remodeling in patients treated with 
primary coronary angioplasty (PCI). 
Methods: in 210 consecutive patients undergoing primary angioplasty, myocardial reperfusion was 
evaluated by means of Myocardial Blush Grade (MBG), TIMI Myocardial Perfusion Grade 
(TMPG), and corrected TIMI frame count (cTFC). Clinical data and the use of abciximab and distal 
protection devices were also analyzed. All patients underwent echocardiographic follow-up at 6 
months to evaluate the contractile recovery and the presence of LV remodeling (increase in end-
diastolic volume ≥20%). 
Results: Mean symptom onset-to-balloon time was 219±96 min. A final TIMI 3 flow was obtained 
in 196 patients (93.8%), but a MBG 3 and a TMPG 3 were observed only in 87 patients (41.6%) 
and in 78 patients (37.3%), respectively. Mean final cTFC was 27.7±9.6 f/s. A filter-based distal 
protection device was used in 41 patients (19.5%), of whom 26 (12.4%) also received abciximab. 
Abciximab alone was used in 116 patients (56%). LV remodelling occurred in 45 patients (22%), 
and was associated with: shock (P<0.001), baseline LV ejection fraction<40% (P<0.001), anterior 
wall infarction (P=0.04), final TIMI <3 flow (P<0.001), cTFC>40 f/s (P=0.002), MBG 0-1 
(P<0.001), TMPG 0-1 (P<0.001) and peak creatine kinase (P<0.001). Use of abciximab and/or 
distal protection devices was not associated with a lower rate of LV remodelling. At multivariate 
analysis, only MBG 0-1 (P<0.001), LV ejection fraction<40% (P=0.048) and CK peak (P=0.036) 
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were independent predictors of LV remodelling. In the prediction of 12-month major adverse 
cardiac events, the only independ predictor was MBG 0-1. 
Conclusion: The assessment of MBG is a feasible and simple method to evaluate the effectiveness 
of myocardial reperfusion during primary angioplasty and predicts LV remodelling and clinical 
prognosis. MBG should routinely be used for the prognostic stratification of patients undergoing 
primary angioplasty.
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INTRODUCTION 
 
Reperfusion therapy is by far the most important therapy for the treatment of acute myocardial 
infarction (AMI) (1-2) The success of fibrinolytic therapy and, more recently, of primary 
percutaneous coronary angioplasty (PCI), has drastically reduced the mortality of patients with 
AMI.  The superiority of percutaneous revascularization over pharmacologic treatment has been 
widely documented. The benefits of early reperfusion in AMI include limiting to the size of 
infarction, thus improving left ventricular function and survival. Timely restoration of normal 
antegrade flow and tissue-level perfusion leads to greater limitation of infarct size, preservation of 
myocardial function (3-4), thus resulting in significantly improved survival. 
The correlation between sustained patency of the infarct related artery and improved outcomes 
culminated in the “open-artery hypothesis,” which has been the cornerstone of therapeutic strategies 
for AMI for over a decade. The open-artery hypothesis suggests that re-establishing a patent infarct 
related artery (IRA) with normal anterograde flow salvages stunned myocardial tissue, preserves 
left ventricular mechanical function and positively influences clinical outcomes (5). The benefits of 
IRA patency also may extend beyond myocardial salvage, because late restoration of IRA patency 
does not improve global left ventricular function, but appears to improve long-term survival (7). 
Approximately 25% of patients with restoration of normal anterograde flow in the epicardial IRA, 
however, do not have reperfusion of the myocardium at the tissue level (8). Thus, the open-artery 
hypothesis may be an oversimplification, because the goal of reperfusion therapy should be to 
restore not only upstream epicardial patency and flow, but also downstream myocardial tissue 
perfusion (9). Despite significant advances in the pathophysiological comprehension and in the 
treatment of acute myocardial infarction over the last decades, a more precise and comprehensive 
definition of “optimal reperfusion” is still needed so that a clear target for new therapies can be 
established (10). 
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NO-REFLOW PHENOMENON: PATHOPHYSIOLOGY 
Because total coronary artery occlusion was found in the early hours of transmural myocardial 
infarction, most of research interest and treatment strategies focus on epicardial coronary arteries 
(11). Little attention, however, is paid to the coronary microvasculature. When a coronary artery is 
occluded, detrimental changes occur in the cardiac capillaries and arterioles. After relief of the 
occlusion, blood flow to the ischemic tissue may still be impeded, a phenomenon known as no 
reflow (12). 
Microvascular damage, subsequent to prolonged coronary occlusion, can prevent restoration of 
normal blood flow to myocites. This phenomenon is more pronounced with longer periods of 
coronary occlusions (13). Experimental animal studies and clinical investigations consistently 
demonstrated a close correlation between zones of microvascular obstruction and myocardial 
necrosis. Electron microscopic examination of tissue within anatomic no-reflow zones revealed 
significant microvasculature obstruction by red and white cells or other necrotic debris and  
interstitial edema (14). These changes could compress the capillaries and be responsible for the no-
reflow phenomenon. Finally, microemboli of atherosclerotic debris and blood clots are released into 
the microcirculation, particularly with restoration of normal flow by angioplasty or stenting.  
An inadequate perfusion at the tissue level may explain the lack of contractile recovery in spite of a 
TIMI 3 flow grade. Moreover, a significant correlation between the extent of no-reflow and left 
ventricular remodelling has been demonstrated (15). 
 
LEFT VENTRICULAR  REMODELLING 
Left ventricular (LV) dilatation after myocardial infarction is a major predictor of prognosis and 
identifies which patients will develop heart failure. This process is progressive, starting immediately 
after MI and evolving in the chronic phase of heart failure (16). Through long-term left ventricular 
chamber dilatation and increased wall stress, it can result in alteration of the contractile properties 
 7 
of the non-infarct zone, impairment of the systolic and diastolic performances of the left ventricle, 
and eventually congestive heart failure (17).  
 
Definition 
Ventricular remodelling after acute myocardial infarction is characterized by alteration in LV size, 
shape, and wall thickness and involves both the infarcted and the noninfarcted regions of the 
ventricle. These structural changes are the result of several distinct pathologic processes that 
contribute to progressive LV dilation: rearrangement of wall structure, myocyte hypertrophy, and 
increasing muscle mass without an increase in wall thickness (eccentric hypertrophy). The 
pathogenesis of LV remodelling after AMI is multifactorial. Multiple factors may in fact contribute 
at different stages from the time of coronary occlusion until the development of ventricular dilation. 
These include the magnitude of the loss of contractile elements, the abrupt alteration in systolic and 
diastolic loading conditions, the activation of circulating neurohormones and local autocrine trophic 
factors, and the patency of the infarct-related artery. Although remodelling occurring early after 
infarction may be an appropriate compensatory response to preserve ventricular function, recent 
observations have suggested that this long process has a deleterious effect on LV function and 
prognosis. Thus attempts to inhibit these structural changes have been the focus of recent 
experimental and clinical studies (18). 
 
Pathophysiology 
In detail, the pathophysiology of remodelling is based on a complex series of progressive adverse 
effects takes place, including: (1) non-contractile and potentially expanding scar tissue forming in 
the infarcted zone; (2) the volume load induced by such expansion; and (3) the pressure load 
induced by the increased volume load. Additional ischaemic insults could also contribute to 
remodelling. Thus, a mixed pressure and especially volume load exists, with remodelling of the 
entire left ventricle in proportion to infarct size, with a fall in ejection fraction in direct relation to 
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the size of the infarct. However, the increase in the LV volume augments the stroke volume by the 
Starling mechanism so that cardiac output is relatively normal (19-20-21). Therefore, early post-
infarct remodelling could be beneficial and promote survival, but with deleterious long-term 
haemodynamic consequences. In anteroseptal infarcts, the crucial issue enlarging the left ventricular 
volume is the early increase in apical regional wall stress (22). Late ventricular enlargement is not 
the result of progressive infarct expansion, but rather is caused by an increase in the length of the 
remaining contractile tissue (23), which is the pattern of volume overload. Long-term progressive 
remodelling of the left ventricle with increases in the ventricular cavity size can occur up to 2 years 
post-infarct with increased cardiovascular death even in patients treated with ACE inhibitors. 
Conversely, seemingly minor reductions in remodelling can be associated with decreased heart 
failure and cardiovascular death (24). 
 
Histological changes 
The histological changes are the expression of molecular, cellular and interstitial changes in 
response to cardiac injury, manifesting as adverse alterations in the size, shape and function of the 
ventricle. The most critical determinant of the remodelling is the magnitude of the acute infarct (i.e., 
the number of dead cardiomyocytes resulting from the acute ischemic insult). The ultimate size of 
acute infarct, which can be determined within several hours after the onset (25), is the most critical 
determinant of subsequent heart failure. In addition, other factors, including late death or 
hypertrophy of cardiomyocytes, fibrosis and the expression of various cytokines, are associated 
with the continued disease progression during the chronic stage. Notably, apoptosis has been 
detected in the heart during all stages of MI, suggesting apoptosis may be responsible for a 
significant amount of cardiomyocyte death during the acute ischemic stage, as well as for a 
progressive loss of surviving cells during the subacute and chronic stages. 
Loss of cardiomyocytes during either the acute or chronic stage of MI directly contributes to 
contractile dysfunction. In addition, apoptosis is now suggested to be involved in the acute ischemic 
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death of cardiomyocytes, as well as in the dropout of surviving cardiomyocytes during the chronic 
stage of MI. During the subacute phase of MI, the nonmyocyte population increases due to both 
proliferation and infiltration, affecting post-infarction remodelling through the synthesis of 
extracellular matrix and/or the secretion of cytokines and local hormones that interact with 
cardiomyocytes and nonmyocytes alike (26). The extra nonmyocytes in the heart that accumulate 
following MI are then cleared during the chronic stage via apoptosis (27-28). 
Inflammatory response and cytokine elaboration are also involved in the setting of left ventricular 
remodelling after AMI. They are integral components of the host response to tissue injury and play 
a particularly active role after myocardial infarction. The degree of the inflammatory response in 
turn is an important determinant of the host’s outcome. Cytokines are released by the host 
myocardium to modulate tissue repair and adaptation after injury.  
The consequences of inflammatory cytokine effects can be favorable, leading to healing and 
restoration of function, or unfavorable, leading to acute cardiac rupture or chronic dilatation, paving 
way for heart failure.  
The stimulation of cytokine secretion in response to myocardial ischemia or infarction has profound 
effects on myocardium that provokes at least four changes directly in cardiac myocytes that 
contribute to the phenotype reprogramming or remodelling: progressive myocyte apoptosis, 
myocyte hypertrophy, defects in contractility, and inflammatory signal transduction. Chronically, 
cytokines have additional effects on extracellular matrix, integrins, and vascular and cardiac 
regeneration. Among the cytokines, TNF-, IL-1ß, and IL-66,7 are most commonly associated with 
the remodelling process postmyocardial infarction (29). 
Cytokines such as tumor necrosis factor-alpha (TNF-) or interleukin-6 (IL-6) are elaborated soon 
after myocardial ischemic injury and can acutely regulate myocyte survival or apoptosis and trigger 
additional cellular inflammatory response. Chronically, cytokines can mediate repair and 
remodelling through activating matrix metalloproteinases and collagen formation, and regulate 
integrins and angiogenesis and progenitor cell mobilization.  
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In the post-infarct period, enhanced activity of metalloproteinases breaks down the existing 
collagen while promoting the formation of new collagen that is poorly crosslinked,3,99,100 opie 
which in turn could explain the side-to-side slippage of myocytes that hypothetically contributes to 
ischaemic ventricular remodelling (30). The standard argument for slippage is elongation of 
myocytes with thinning of the left-ventricular wall. Other explanations include altered myocyte 
transverse shape, from round to ellipsoid. 
Several clinical studies have documented significant elevations in the levels of renin, angiotensin II 
(Ang II) and aldosterone attending acute myocardial infarction and/or congestive heart failure. 
Similar to catecholamines, markedly elevated activity of the renin-angiotensin-aldosterone system 
(RAAS) is associated with poor prognosis. The effects of Ang II upon cardiac tissue are related to 
two primary receptors, Ang II type 1 (AT1) and Ang II type 2 (AT2). The AT1-receptor appears to 
mediate many of the deleterious effects of chronic RAAS activity, while the AT2-receptor is 
increasingly shown to have potential cardioprotective effects. Attenuating the deleterious effects of 
sustained Ang II stimulation can be achieved by direct inhibition of angiotensin- converting enzyme 
(ACE) and/or direct antagonism of AT receptors. ACE inhibition reduces left ventricular (LV) 
volumes, retards the progression of LV dilatation and hypertrophy and increases systolic function in 
systolic dysfunction. By blocking at the receptor level, Ang II receptor blockers (ARBs) provide an 
alternative and more direct approach to inhibiting the effects of Ang II; however, data relating to 
their effects upon ventricular remodelling, whether used in isolation or in combination with ACE 
inhibitors (ACE-Is), are less convincing. Data arising from several recent clinical trials suggest that 
simultaneous use of ACE-Is and ARBs maybe of more benefit in attenuating ventricular 
remodelling than either agent alone (31).  
The processes of LV remodelling and healing after AMI are dynamic and time-dependent, and 
progress in parallel. Thus, remodelling spans the phases of infarction, healing before and after 
collagen deposition, and subsequent scar formation. 
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CONTRACTILE RECOVERY 
After AMI, left ventricular function is the most important predictor of long-term prognosis and is 
strongly related to a prompt and successful restoration of adequate flow in the occluded artery in 
AMI patients. It has been demonstrated that more timely reperfusion, particularly when it is within 
6 h of symptom onset, leads to greater limitation of infarct size and preservation of myocardial 
infarction (32). 
In clinical practice, patients may have variable recovery of the left ventricular (LV) function after 
successful primary PCI and contractile recovery itself can occur at different time after AMI. 
Ventricular function may be impaired for days to weeks following achievement of even complete 
reperfusion, due to a phenomenon that has been termed ‘myocardial stunning’ — profound 
metabolic derangement due to prolonged ischaemia that impairs ventricular systolic and diastolic 
performance, but is insufficient to cause cell death. Therefore, assessment of ventricular function 
after reperfusion therapy for acute myocardial infarction should be performed a few months after 
infarction to detect late improvement in ventricular function, should myocardial stunning have 
occurred (33). 
Over 4 years period the Zwolle’s group (Netherlands), leader in primary PCI, treated 785 
consecutive patients with primary PCI (34); the 6-month mortality in this unselected group was 
only 5% and 3 % had a recurrent non-fatal AMI. However, analysis of 600 patients with impaired 
ejection fraction measured by radionuclide ventriculography on the 4th day and 6 months after 
infarction showed a significant improvement in left ventricular function in 48 % of the patients, a 
decrease in 25 % whereas in the remaining patients there was no significant change. In other words, 
it seems that only in less than 50% of our successful interventions we are producing salvage of 
myocardium that we can measure overtime. Independent predictors of recovery included anterior 
site of infarction, and more severely depressed ejection fraction at baseline. These two groups of 
patients and more significantly the combination of those characteristics, should represent a priority 
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in the selection of patients with AMI to submit to primary PCI, due to a more evident benefit in LV 
recovery. 
 The deterioration or the lack of significant improvement of LV function at 6 months may be due in 
part to transient hyperkinesia of the non-infarcted area in the acute phase, further loss of myocardial 
function  or expansion of the infarcted zone. On the other hand, the presence of myocardial viability 
is responsible for  contractile recovery within days/weeks after reperfusion.  
Several studies have demonstrated a strong association between the amount of stunned myocardium 
and contractile recovery (35-36). Different diagnostic techniques have been used in order to assess 
viability, based on the detection of inotropic reserve, microvascular perfusion, coronary flow 
reserve, metabolic activity. In spite of the relevant contribution provided to a better understanding 
of the pathophysiologic insights, the widespread of such diagnostic tools in clinical practice is still 
limited by costs, logistic problems and not well proved reproducibility of most of them.  
 
 
TOWARD A BETTER ASSESSMENT OF MYOCARDIAL PERFUSION 
Myocardial salvage is the hallmark of successful reperfusion therapy. Advances in non-invasive 
functional imaging has allowed the application of these concepts on a large scale to patients treated 
with primary PCI (37). Several diagnostic techniques have been developed in order to better 
identify the no-reflow phenomenon.  
 
Direct assessment of tissue perfusion 
Myocardial infarction reperfusion no-reflow was first documented by Schofer et al. by using dual 
myocardial scintigraphy in a patient before and after thrombolysis for acute myocardial infarction 
(38). The work is still considered as the first evidence for the no-reflow phenomenon in humans. 
Since then, numerous experimental and clinical studies have demonstrated the validity of 99mTc-
sestamibi myocardial imaging for determination of infarct size (39) and fibrosis in myocardium 
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(40). In other studies, 99mTc-sestamibi infarct size has been demonstrated to be a strong predictor 
of mortality (41-43). In a series of 274 patients with acute myocardial infarction, sestamibi infarct 
size was strongly associated with 2-y mortality (40). In a recent multicenter study from the same 
group comprising a series of 249 patients with acute myocardial infarction, a strong association 
between 99mTc-sestamibi infarct size at hospital discharge and 1-year mortality was reported (42). 
In the STOPAMI trials 1 and 2, salvage index was a sensitive tool to evaluate the efficacy of 
different interventional and thrombolytic reperfusion therapies in patients with acute myocardial 
infarction (44-45). 
Myocardial contrast echocardiography (MCE) is a non invasive technique capable of providing 
information on the anatomy and function of the microcirculation, in vivo. It employs an 
intravascular perfusion tracer detected by ultrasound procedures during its passage into the 
microvessels. If performed by selective intracoronary injection, myocardial contrast 
echocardiography yields to the comprehension of the correlation existing between coronary 
anatomy and intramyocardial perfusion (46-47). Several studies have been performed in order to 
assess the ability of MCE  for the detection of stunning myocardium after reperfused AMI. Ito 
demonstrated a strong correlation between no-reflow phenomenon assessed with intracoronary 
MCE and left ventricular dilatation at one-month follow-up (48). Further studies have been 
performed using intravenous MCE for the prediction of LV remodelling, confirming the 
aformentioned data collected by Ito with the intracoronary MCE.(49-50)  
Associated with pharmacologic tests, MCE can also provide a functional assessment of 
microvasculature, thus allowing a qualitative and quantitative analysis of microvascular coronary 
reserve (51). 
Other myocardial imaging techniques such as nuclear magnetic imaging and positron emission 
tomography have also been shown to be useful diagnostic tools for no-reflow (52-54). The major 
disadvantages of these investigations are their costs and technical difficulty. Their application 
remains limited to highly specialized and research centres. 
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Contrast-enhanced MRI can directly distinguish between reversible and irreversible ischemic injury 
within the region at risk, by assessing microvascular perfusion. Recently, Wu et al documented in 
humans the association between presence of microvascular obstruction by MRI and worse chronic 
long-term prognosis (55).  Transmural extent of hyperenhancement by contrast enhance-MRI 
performed early after MI is inversely related future improvement in contractile function. 
Hillenbrand and collegues found that segments for which the transmural extent of hyperhenacement 
at 3 days was > 75% were unlikely to exhibit improved wall thickening at 4 weeks (56).  
Conversely 87% of segments for which the transmural extent of hyperhenancement was < 25% at 3 
days exhibited improved thickening by 28 days. Loss of sarcomere membrane integrity after acute 
cellular injury may allow gadolinium chelate to enter the intracellular space, thereby increasing the 
myocardium concentration of Gd and resulting in hyperhenancement.  
 
Surrogates for myocardial perfusion   
Recent investigation has demonstrated the usefulness of a simple standard ECG in the diagnosis of 
myocardial infarction reperfusion no-reflow. Santoro et al.(57) studied the relationship between ST-
segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in 
patients with acute myocardial infarction treated with primary PCI. All patients had restoration of 
TIMI 3 flow after intervention. A rapid ST-segment decrease was highly specific (91%) for 
myocardial reperfusion (or the absence of no-reflow on myocardial contrast echocardiography) 
although less sensitive (77%).  
Prognostic significance of ST segment resolution has been provide, as well. In GISSI Study group 
(Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico) patients with ≥50% ST 
resolution 4 h after thrombolysis had a lower 30-day mortality rate (58). The prognostic value of ST 
segment resolution was confirmed  for patients treated with primary PCI (59). In a subgroup of 700 
patients of the Cadillac trial, ST segment resolution  after primary PCI in AMI was strongly 
correlated with mortality and reinfarction, independent of target vessel patency. The simple measure 
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of the maximal residual degree of ST segment elevation after primary PCI was the strongest 
independent predictor of both survival and freedom from reinfarction at 1-year (60).   
Contractile reserve represents the effect of an adequate tissue perfusion and thus of myocardial 
salvage. Thus, techniques able to detect contractile reserve are clinically used to assess myocardial 
viability after AMI. Such techniques are based on the assumption that, despite severe resting 
dysfunction, reversibly injured myocardium might retain the ability to improve function temporarily 
upon stimulation with catecholamines or calcium, whereas infarcted myocardium does not. The 
ability of acutely stunned myocardium to improve function upon inotropic stimulation has been 
known for several years (61-62). Low dose dobutamine echocardiography is one of the currently 
available techniques for determining the presence of viable myocardium. By recognizing this tissue 
as viable, improvement is likely to occur after revascularization. In 40 pts after AMI contractile 
response to dobutamine was assessed within 5 day after primary PCI. Sensitivity and specificity of 
dobutamine echocardiography in predicting improvement in contractile function at follow-up were 
82% and 83%, respectively (63). Other studies were performed showing a sensitivity ranging from 
66–86% and a specificity from 68–94% (64-67). All those studies have concentrated exclusively on 
predicting reversible dysfunction on a regional basis. Comparative studies have also been 
performed between low-dose dobutamine echocardiography and intravenous MCE for the 
prediction of contractile recovery. Dobutamine echocardiography had a sensitivity and a negative 
predictive value similar to MCE in predicting late functional recovery (89% vs. 96% and 93% vs. 
89%, respectively), with a significantly higher specificity (91% vs. 18%, p < 0.001), positive 
predictive value (86% vs. 41 %, p < 0.001) and overall accuracy (90% vs. 47%, p < 0.001)(68). 
Low-dose dobutamine echocardiography was superior to intravenous MCE in the prediction of 
functional recovery of akinetic myocardium after AMI, but the combination of both maximizes 
predictive accuracy (69). 
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Angiographic methods have been developed in order to assess tissue perfusion  
Angiographic no-reflow should be suspected when there is reduced TIMI flow, as first described by 
Wilson et al.(70). It needs to be differentiated from other causes of slow flow due to epicardial 
obstruction caused by dissection, thrombus, prolonged spasm, distal macroembolization or 
competitive flow obscuring satisfactory antegrade opacification. If interpreted with caution, 
coronary angiography is still an essential and simple way to diagnose any clinical form of no-
reflow. However, up to 25% of patients with TIMI 3 flow has an inadequate microvascular 
perfusion and this has led to the development of other angiographic methods for the assessment of 
microvascular perfusion. 
Corrected TIMI frame count (CTFC) is an objective, reproducible measure of coronary blood flow, 
in which the number of cineframes required for dye to reach standardized distal landmarks are 
counted; this is essentially a measure of the time for dye to go down the artery (71-72). In several 
studies an association between the CTFC and clinical outcomes among patients treated with 
primary PCI has emerged, and the CTFC has demonstrated greater sensitivity in detecting 
improvements in epicardial flow compared with the use of TIMI grade 3 flow among patients 
treated with new device interventions (73-74). Myocardial blush, based on the contrast dye density 
and washout in the infarcted myocardium, is a simple tool that correlate significantly with tissue-
level perfusion shortly after recanalization of the infarct-related artery  (75).  
Intracoronary Doppler measurements may be extremely helpful to diagnose angiographic no-
reflow. Iwakura and colleagues (76) described a typical Doppler pattern of angiographic no-reflow: 
a reduced or even absent antegrade systolic flow followed by a retrograde systolic flow and rapid 
deceleration of diastolic flow. These authors postulated that the intramyocardial blood pool in 
patients with no-reflow is markedly reduced because of severe microvascular obstruction. Such a 
condition would explain the rapid diastolic flow deceleration as the myocardial blood pool is 
rapidly filled during diastole. This pooled blood is then partially expelled back into the epicardial 
coronary artery capacitor during systole, producing retrograde systolic flow. 
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Myocardial blush 
Multiple lines of evidence indicate that impaired tissue perfusion can be present even despite 
restoration of normal epicardial flow. Van’t Hof and Gibson created two different angiographic 
methods in order to detect no- or slow-flow, beyond TIMI 3. 
In 1998 Van’t hof first introduced myocardial blush grade in the study of microvascular perfusion 
in patients with AMI. He based his studies on the evidence that myocardial perfusion could be 
assessed visually with intracoronary injection of sonicated microbubbles during echocardiography 
in the catheterization laboratory. This technique had been used to describe the effectiveness of 
myocardial reperfusion and predict clinical outcome.8,9description (77). 
Because the venous phase of the coronary angiogram was often clearly visible in patients with no 
reflow, the echocardiographic or angiographic contrast agent passed from the arterial coronary 
vessels into the venous system by another route than the myocardial microcirculation in the infarct 
zone. Thus, he developed the angiographic myocardial blush grade based on the visually assessed 
contrast density in the infracted myocardium after reperfusion therapy. Myocardial blush grades 
were defined as follows: 0, no myocardial blush or contrast density; 1, minimal myocardial blush or 
contrast density; 2, moderate myocardial blush or contrast density but less than that obtained during 
angiography of a contralateral or ipsilateral non–infarct-related coronary artery; and 3, normal 
myocardial blush or contrast density, comparable with that obtained during angiography of a 
contralateral or ipsilateral non–infarct-related coronary artery. When myocardial blush persisted 
(“staining”), this phenomenon suggested leakage of the contrast medium into the extravascular 
space13 and was graded 0. 
The angiographic myocardial blush grades are analogous to the TIMI grades flow in the epicardial 
infarct–related coronary artery. This information can be obtained during routine high-quality 
coronary angiography and can be used to describe the effectiveness of reperfusion therapies. He 
pointed out the concept that , at the time of coronary reopening, myocardial reperfusion is achieved 
only in areas with anatomically preserved microvasculature, whereas reflow does not occur in 
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myocardium with extensive microvascular damage. The noreflow phenomenon is therefore 
associated with relatively more extensive necrosis and, as a consequence, is a predictor of poor 
regional and global contractile function.(78). Contrariwise, adequate myocardial reflow shortly after 
epicardial coronary reperfusion is an accurate indication of microvascular integrity and 
consequently, of regional and overall functional recovery in patients with acute myocardial 
infarction.(79). 
Two years later, in 2000, Gibson published new data on the development and use of a simple 
semiquantitative classification scheme, the TIMI myocardial perfusion grade (TMP), that could be 
used to characterize the filling and clearance of myocardial perfusion from a coronary angiogram 
(80). This filling appeared as a myocardial blush, the ground-glass appearance of the myocardium 
on the coronary arteriogram. Similarly to van’Hof’s method, he assigned four scores to TMP, but 
the innovative issue as compared to the previous study, consisted of the assessment of both entrance 
and exit of dye from the microvasculature. In particular, TMP grades were as follows:  
TMP Grade 0 : Failure of dye to enter the microvasculature. Either minimal or no ground-glass 
appearance (“blush”) or opacification of the myocardium in the distribution of the culprit artery, 
indicating lack of tissue-level perfusion. TMP Grade 1: Dye slowly enters but fails to exit the 
microvasculature. There is the ground-glass appearance (“blush”) or opacification of the 
myocardium in the distribution of the culprit lesion that fails to clear from the microvasculature, and 
dye staining is present on the next injection (;30 seconds between injections). TMP Grade 2: 
Delayed entry and exit of dye from the microvasculature. There is the ground-glass appearance 
(“blush”) or opacification of the myocardium in the distribution of the culprit lesion that is strongly 
persistent at the end of the washout phase (ie, dye is strongly persistent after 3 cardiac cycles of the 
washout phase and either does not or only minimally diminishes in intensity during washout). TMP 
Grade 3: Normal entry and exit of dye from the microvasculature. There is the ground-glass 
appearance (“blush”) or opacification of the myocardium in the distribution of the culprit lesion that 
clears normally and is either gone or only mildly/moderately persistent at the end of the washout 
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phase (ie, dye is gone or is mildly/moderately persistent after 3 cardiac cycles of the washout phase 
and noticeably diminishes in intensity during the washout phase), similar to that in an uninvolved 
artery. Blush that was of only mild intensity throughout the washout phase but fades minimally was 
also classified as grade 3. 
 
 
EFFECTIVE MYOCARDIUM REPERFUSION WITH CURRENT PCI INTERVENTIONS: 
THERAPEUITIC IMPLICATIONS 
Several studies have been performed in order to test the efficacy of drugs for the prevention of "no-
reflow" phenomenon. 
Adenosine has shown to have pharmacological actions against detrimental effects of neutrophils 
involved in the no-reflow phenomenon and its possible protective effect has been investigated in 
relatively large placebo-controlled clinical trials (81).  In the AMISTAD trial, the final infarct size 
in pts with AMI undergone to thrombolysis was reduced and the LV systolic function was improved 
by adenosine treatment, mainly in patients with anterior AMI localization. However, morbidity and 
mortality were not affected (82). In the ADMIRE study, a novel adenosine agonist was tested in 311 
patients undergoing primary PCI; it did not reduce infarct size, but only a trend toward greater 
myocardial salvage in treated patients with anterior AMI was found (83). In a recent study, 79 pts 
with AMI received received intracoronary adenosine during successful primary PCI. Myocardial 
reperfusion, assessed by degree of persistent ST elevation despite restoring vessel patency, was 
more complete in patients treated with adenosine, without any significant clinical impact on 
prognosis at one-month (84). The possibility of obtaining a TIMI grade 3 flow in the infarct-related 
artery in up to 95% of patients with AMI (increasing the occurrence of reperfusion injury) has 
turned back the interest towards the protection of myocardial cells from the impending ischemic and 
reperfusion injury in which adenosine alone or together with other cardio-protective agents may 
exert important clinical effects. 
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The effect of glycoprotein IIb/IIIa inhibitors and/or stents on myocardial perfusion have been 
recently investigated. Tissue-level perfusion as assessed by the myocardial blush grade was 
evaluated at a core angiographic laboratory in 1301 CADILLAC patients with AMI randomized to 
balloon angioplasty versus stenting, each with or without abciximab (85). 
Despite restoration of TIMI-3 flow in 96.1% of patients, myocardial perfusion was absent in 48.7% 
of patients, reduced in 33.9%, and normal in only 17.4%. Patients with AMI involving the LAD 
were particularly unlikely to have normal myocardial perfusion restored after primary PCI.   
Myocardial blush grade was unrelated to procedural parameters, neither stents nor glycoprotein 
IIb/IIIa inhibitors significantly enhanced myocardial perfusion compared to balloon angioplasty 
alone. Baseline TIMI 3 flow correlates of obtaining optimal myocardial reperfusion were identified. 
Myocardial perfusion status post-PCI stratified patients into distinct risk categories, with 1-year 
mortality rates of 1.4% (normal blush), 4.1% (reduced blush), and 6.2% (absent blush) (p=0.01). 
AMISCOPE was specifically designed as a mechanistic substudy of the CADILLAC trial to 
evaluate clinical events, regional contractile recovery and related morphologic-physiologic causes 
in patients with AMI undergoing successful contemporary primaty PCI (86). This study  was 
conducted with multiple use of highly sophisticated imaging techniques (coronary angioscopy, 
intravascular ultrasound, doppler flow guidwire and regional wall motion analysis) at different time 
points (immediately after primary PCI, at 24 hours, and 7 months follow-up).  The findings, 
obtained through an independent Core Lab, confirm that despite  TIMI 3 flow grade could be easily 
reached in almost all patients (94%), it is very likely that after successful primary PCI,  residual 
mural thrombus, extensive surface disruption and prolonged impaired  coronary flow reserve 
remain in infarct related artery.  By multiple linear regression analysis the assigned treatment was 
not an independent predictor  for recovery in regional wall motion while TIMI 2-3 flow grade 
before the intervention was (TIMI 0-1 vs TIMI 2-3 before PCI: Abnormal chord at 7 months (n) 
28±16 vs 6±10, P<0.001; Wall Motion Index (SD/ch) 1.4±1.3 vs   2.8±2.3, P<0.05;  7 months 
LVEF 55±10 vs 67±5, P<0.001). 
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Prevention of Distal Embolization 
Distal embolization of thrombus or plaque components during primary PCI may play a role in 
limiting the effective myocardial reperfusion. Whereas stent implantation undoubtedly reduces 
restenosis and infarct-artery reocclusion compared to balloon angioplasty, concerns arose regarding 
increased rates of distal embolization after stenting, resulting in diminished microcirculatory 
perfusion and greater mortality. Recently, new devices have been designed to trap embolic material.  
It has been already demonstrated that the adjunctive use of the filter wire  during primary PCI 
allowed capture of emboli demonstrating the presence of platelets, red cells and plaque remnants 
(87).  On the other hand, data from EMERALD trial showed that distal protection with GuardWire 
Plus system during primary PCI does not have a beneficial impact on infarct size or patient 
outcomes compared to angioplasty alone. The trial included 501 patients with AMI randomized 
within 6 hours of chest pain onset. Although GuardWire Plus system was successful in removing 
clot and atheromatous debris from 70% of arteries, complete ST segment resolution was observed 
in 62% of distal protection patients and 60% of those having PCI alone. Similarly, non significant 
difference in infarct size was found between the two groups (it was reduced in 17% of the distal 
protection group and in 16% of the control PCI group) (88).  
 
Further possibilities for Effective myocardium reperfusion: the treatment of ischemic 
cardiomyopathy 
In some animal studies, it has been demonstrated that autologous bone marrow cells contributes to 
neoangiogenesis in the ischemic myocardium (89-93). Based on these studies, direct introduction of 
stem and progenitor cells into the peri-infarct region can facilitate revascularization. This procedure 
involves either direct injection or coronary arterial delivery of stem cells into the peri-infarct area. 
In humans, whole autologous bone-marrow mononuclear cells were delivered by arterial catheters 
into the coronary arteries feeding the infarcted and ischemic tissue (94), by transendocardial 
injections(95), or by guided electrochemical mapping directly into infarcted myocardium (96). In 
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another study, the efficacy of the ex vivo expanded peripheral blood mononuclear cells was 
compared to bone marrow-derived EPCs in restoring revascularization after AMI (97). In all of 
these studies, there was improved blood flow and left ventricular function, suggesting that infusion 
of autologous progenitor cells appears to be feasible, safe and may confer short-term therapeutic 
benefit. 
Despite enthusiasm for these pioneering clinical trials, it remains to be determined in randomized 
clinical trials whether cellular therapy will result in long-standing improvement in cardiac function 
and decrease morbidity and mortality without any long-term toxicity.  
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AIM 
 
The aim of the present study is to identify early angiographic predictors of LV remodelling in 
patients with AMI, successfully treated with primary PCI. In addition, clinical and 
echocardiographic data have been assessed. Predictors of 1-year clinical outcome have been 
investigated, as well. 
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METHODS 
Study population 
Between January  2002 and February 2004  a total of 263 consecutive patients, presenting within 12 
hours of symptom onset, with ST-segment elevation of 1 mm in 2 contiguous ECG leads underwent 
primary PCI in our Department. Six patients with cardiogenic shock died during the procedure. 
Four patients had a suboptimal angiographic result (TIMI flow grade < 2), 19 patients showed left 
bundle branch block or poorly interpretable ST segments, in 11 patients an adequate assessment of 
myocardial blush was not achieved, 4 patients had inadequate echocardiographic image quality, and 
9 patients were lost at follow-up. The remaining 210 patients represent the population of the present 
study. Cardiogenic shock was defined as persistent low systolic pressure (<90 mm Hg) with clinical 
signs of left- or right-sided cardiac failure. Reperfusion time (from beginning of pain to first balloon 
inflation) could be registered in all patients. During hospitalization and at discharge, standard 
therapy was started according to evidence-based practice guidelines. Serial measurements of cardiac 
enzyme release (creatine kinase [CK] with CK-MB isoenzymes) were performed, and the maximum 
level was used as an enzymatic marker of infarct size. Samples were obtained at 4-hour intervals up 
to 18 hours and later at 8-hour intervals up to 72 hours after intervention. 
 
Echocardiographic analysis 
Patients underwent a 2D echocardiogram before primary PCI, at 7 days and at 6 months. Left 
ventricular ejection fraction (EF), regional wall motion score index (WMSI) and left ventricular end 
diastolic volume (EDV) were assessed.  
WMSI was calculated with the model proposed by the American Society of echocardiography. Left 
ventricular volumes were calculated with the use of a modified Simpson's rule from long-axis 
views. 
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All echocardiograms were interpreted by two experienced echocardiographers, blinded to each 
other and unaware of the patient’s treatment and outcome. 
Left ventricular remodelling was considered as an increase of left ventricular end diastolic volume 
>20% compared to basal echocardiogram (13). According to the presence or absence of LV 
remodelling at 6 months after infarction, patients were divided into an LV remodelling group and a 
no LV remodelling group, respectively 
 
Angiographic analysis 
The angiographic images were acquired with a Siemens single-plane system at a cine rate of 25 
frames/s. The analysis was carried out by two Cardiologists who were blinded to the patient’s 
identity and ECG and echocardiographic findings. Basal TIMI flow was evaluated on the first 
angiogram. TIMI flow, corrected TIMI frame count, MB and perfusion grade were graded on the 
angiograms taken immediately after PCI.  
The methodologies for myocardial blush and TIMI perfusion grade analysis (derived from the 
original Zwolle description and Gibson’s classification, respectively) have been previously 
described, and shown to have high intra- and inter-observer reproducibility (77,80). Angiograms are 
considered technically adequate for blush analysis only if the 3 following parameters were fulfilled: 
1) At least one view was present that isolated the myocardial infarct zone; 2) The duration of cine 
filming was required to exceed 3 cardiac cycles in the washout phase to assess washout of the 
myocardial blush 3) Complete arterial opacification with backflow of contrast into the aorta was 
present indicating adequate contrast filling of the epicardial coronary artery without occlusive 
catheter wedging. 
Myocardial blush was graded in the distribution of the infarct artery as previously described based 
on the maximal densitometric degree of contrast opacification: MBG-0/1 = no or minimal 
myocardial contrast opacification; MBG-2 = moderate contrast opacification but less than in either 
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an ipsilateral or contralateral non-infarct artery; and MBG-3, normal myocardial blush or contrast 
opacification, comparable with the other coronary arteries (77). 
TIMI flow grade, according to Gibson classification, was scored as follows: grade 0 was no contrast 
density; grade 1 when dye slowly entered but failed to exit the microvasculature (dye staining was 
present on the next injection after 30 seconds); grade 2 when there was a delayed entry and exit of 
dye from the microvasculature (gone by next injection); grade 3 when dye normally entered and 
exited from the microvasculature (80). 
 
Clinical follow-up 
Patients were clinically followed-up for the occurrence of major adverse cardiac events (MACE) at 
12 months. Adverse cardiac events included death, reinfarction, congestive heart failure, target 
lesion revascularization, and recurrent ischemia. Reinfarction was defined as the occurrence of new, 
significant Q waves in 2 contiguous leads (different from those of the original AMI) or the re-
elevation of creatine kinase-MB and troponin T to above-normal levels. Congestive heart failure 
was defined by the presence of New York Heart Association (NYHA) class III-IV symptoms at the 
follow-up visit. Recurrent ischemia was defined as ischemic chest pain either at rest or on exercise 
testing, with new ST-segment or T-wave changes in the territory of the infarct-related artery.  
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STATISTICAL ANALYSIS 
 
Categorical data are presented as absolute values and percentages, whereas continuous data are 
summarized as mean value ± SD. Chi-squared and Fisher’s exact tests were used for comparison of 
categorical variables as appropriate. Comparison of continuous variables was performed by means 
of Student’s t-test or Wilcoxon rank-sum test, as appropriate. All variables with P<0.10 at 
univariate analysis were included in a stepwise logistic regression analysis. P values <0.05 were 
considered statistically significant. Event-free survival curves for all major cardiac and combined 
events were constructed by use of the Kaplan-Meier method, and statistical differences between 
curves were assessed by log-rank test. We calculated sensitivity, specificity, positive predictive 
value, negative predictive value, and receiver-operating characteristic (ROC) curves for both MBG 
and TMBG, with their 95% CI. The optimal cut point between sensitivity and specificity for the 
prediction of left ventricular remodelling for both techiques was a score of 0-1 indicating no tissue 
perfusion and 2-3 indicating adequate tissue perfusion. 
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RESULTS  
 
Patient characteristics. Baseline clinical and echocardiographic characteristics of patients with and 
without LV remodelling are summarized in table 1. One hundred and ninety-three patients 
completed 6-month echocardiographic follow-up, of whom forty-three (21,9%) showed LV 
remodelling. Patients with LV remodelling more often had a Killip grade 3-4, an anterior infarction 
and a larger enzymatic infarct size. In addition, they had a lower EF and a higher WMSI at basal 
echocardiogram. 
 
Angiographic variables and procedural feature. Table 2 summarizes angiographic and procedural 
data. After PCI, TIMI 3 flow was achieved in 196 patients (93.8%). MBG 3 and TMPG3 were 
observed only in 87 (41,6%) and in 78 patients (37,3%), respectively, 12 patients (5,8%) had MBG 
0 and TMPG 0. Forty-eight patients (23%) and forty-nine patients (23,5%) had MPG and TMPG 0-
1, respectively.   
No difference between patients with and without left ventricular remodelling was found in initial 
TIMI flow, whereas a significantly higher percentage of final TIMI 3 flow was found in patients 
without LV remodelling (98,7% vs 81,4 %; p < 0,001). A significantly lower cTFC was found in 
non-remodelled patients, as well (26,5 ± 8,7 vs 31,7 ± 12,1; p = 0,008). No difference between 
groups was found in the percentage of stent implantation and in the use of filter-wire and/or 
abciximab during the procedure.  
Patients without LV remodelling had a mean MBG and TMPG significantly higher (2,35 ± 0,74 vs 
1,56 ± 0,96, p = 0,001, and 2,29 ± 0,72 vs 1,58 ± 0,98, p<0,001, respectively). End diastolic volume 
changes were significantly related to tissue perfusion, detected with both MBG and TMPG (fig 2-
3). A better tissue perfusion was present in patients without left ventricular remodelling, as 
confirmed by the higher percentage of MBG and TMPG 3 (48,4% vs 20,9, p < 0,01 and 43,8% vs 
20,9%, p < 0,01, respectively) and the lower percentage of MBG and TMPG 0-1 (11,7 % vs 53,5 
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%; p < 0,001, and 13,1% vs 48,8, p < 0,0001), as compared with patients with left ventricular 
remodelling. In the prediction of left ventricular remodelling both MPG and TMPG showed a high 
specificity 88,2 and 86,9%, respectively, with a negative predicted value of 87,1 and 85,8%. 
 
Clinical outcome. Patients were followed-up for 12 ± 3 months. In table 3, all MACEs are listed. 
Twenty-two patients experienced a MACE during this period, with an overall mortality of 6,7%.  
Fourteen patients had nonfatal AMI, fourteen patients had recurrent angina and fifteen patients 
underwent new revascularization. Myocardial blush grade could strongly predict clinical outcome 
(fig 4). The percentage of MACE was significantly higher among patients with LV remodelling 
(27,9% vs 15%; p=0.04), with a higher mortality even though not statistically significant. 
 
Predictors of LV remodelling and clinical outcome. As reported in Table 4, an inadequate tissue 
perfusion, as defined as MBG 0-1, was an independent predictor of both 6-month LV remodelling 
and one-year MACE (p=0.03 and p=0.001, respectively). Peak of CK and EF at basal 
echocardiography independently predicted LV dilation, but were not independently associated to 
adverse clinical outcome.  
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DISCUSSION 
 
In the present study, more than one-fourth of patients developed left ventricular remodelling, 
although a prompt, successful mechanical reperfusion of the infarct related artery was obtained in 
the majority of cases. Final TIMI flow 3 in the infarct related artery was more often achieved in 
non-remodelled patients, but this variable was not an independent predictor of left ventricular 
remodelling at multiavariate analysis. On the other hand,  microvascular perfusion, as assessed with 
both MBG and TMPG, strongly correlated with left ventricular dilation, independently of the final 
flow in the epicardial vessel. Microvascular impairment, defined as a perfusion score 0-1, emerged 
to be a significant independent predictor of LV remodelling, showing a very high specificity.  
These data highlight the concept that a successful reperfusion of the epicardial vessel is necessary 
but not sufficient to provide an optimal myocardial reperfusion. Moreover, this is the first study 
where both angiographic methods are used simultaneously in the same population and appear to be 
equivalent in the assessment of microvascular perfusion after primary PCI. Both methods seems to 
be feasible, reproducible and show similar sensitivity and specificity in the prediction of left 
ventricular remodelling after AMI, even though at multivariate analysis only MBG is an 
independent predictor of left ventricular remodelling and MACE. 
 
From Effective Epicardial to Effective Myocardial Blood Flow 
For two decades the goal of reperfusion has been restoration of normal epicardial blood flow. 
However patency of the infarct related artery does not always guarantee salvage of myocardium at 
risk. Up to 25% of patients with AMI do not have adequate restoration of myocardial tissue 
perfusion in the infarct zone, despite TIMI 3 flow grade in the epicardial vessel (98-101). It has 
become increasingly apparent that not all TIMI grade 3 flow is created equal and attention has 
shifted downstream to the restoration of normal myocardial perfusion. It has become increasingly 
apparent that clinical outcomes are not only associated with angiographic flow in the epicardial 
 31
artery, but also with angiographic flow in the myocardium (102-105). To this end, the goal of 
reperfusion therapies has shifted to include reperfusion downstream at the level of capillary bed, 
and it might be more appropriate that the hypothesis now be termed “the time dependent open artery 
and open microvascular hypothesis”. No-reflow describes compromised tissue perfusion despite 
restoration of epicardial vessel patency. The incidence and extent of early no-reflow is a strong 
predictor of persistent contractile dysfunction and worse left ventricular remodelling (104-107). 
 
Comparison with previous studies 
Several techniques are now available in order to study tissue perfusion, but they are often expensive 
and time consuming. Assessment of microvascular perfusion by contrast echocardiography, 
positron emission tomography and doppler guide wire have revealed the no or low-reflow 
phenomenon in a significant percentage of patients with TIMI 3 flow of the IRA. Contrast 
echocardiography, performed either intracoronary or intravenously,  has correlated the presence of 
contrasts perfusion defects with poor functional recovery after successful recanalization of IRA 
(102).  
Among angiographic techniques, MBG and TMPG are simple markers of myocardial reperfusion 
that correlate with left ventricular functional recovery and mortality, independently of TIMI grade 
flow. Few data exist, however, about their correlation to left ventricular remodelling and no study 
has been previously performed using both methods simultaneously in the same population.  
In more than 700 patients with AMI, treated with thrombolysis, Gibson demonstrated a mortality 
gradient across the TMP grades, with mortality lowest in those patients with TMP grade 3 (2.0%), 
intermediate in TMP grade 2 (4.4%), and highest in TMP grades 0 and 1 (6.0%). Even among 
patients with TIMI grade 3 flow in the epicardial artery, the TMP grades allowed further risk 
stratification of 30-day mortality(80). Microvascular perfusion with MBG was assessed in patients 
after primary PCI by Van’t Hoff et al. PCI; MBG emerged to be a strong angiographic predictor of 
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mortality, being related also to enzymatic infarct size and residual left ventricular ejection fraction 
(77).  
Tissue-level perfusion as assessed with MBG was also evaluated at a core angiographic laboratory 
in 1301 CADILLAC patients with AMI randomized to balloon angioplasty versus stenting, each 
with or without abciximab (85). Despite restoration of TIMI-3 flow in 96.1% of patients, 
myocardial perfusion was absent in 48.7% of patients, reduced in 33.9%, and normal in only 17.4%. 
Myocardial perfusion status post-PCI stratified patients into distinct risk categories, with 1-year 
mortality rates of 1.4% (normal blush), 4.1% (reduced blush), and 6.2% (absent blush) (p=0.01).  
 
Clinical implications: A suboptimal microvascular flow seems to play a relevant role in the 
development of left ventricular dilation after a reperfused acute myocardial infarction.  
LV dilation is a well recognized determinant of the development of chronic heart failure and is able 
to negatively influence prognosis in patients recovering from myocardial infarction (108-109). 
Clinical implications of left ventricular remodelling are well known and are confirmed by the 
present data, which show the significantly higher incidence of MACEs in remodelled patients as 
compared to those patients who did not develop left ventricular dilation. In the present study, 
patients with a poorer outcome had achieved an inadequate perfusion at MBG and TMPG after 
primary PCI. Angiographic assessment of microvascular perfusion, thus, performed immediately 
after mechanical revascularization of an acute myocardial infarction, in the “Cath Lab”, can predict 
patient prognosis early after AMI. Thus, the goal of reperfusion therapy is gradually and 
progressively shifting from upstream prompt restoration of epicardial flow to downstream 
myocardial tissue perfusion (110).  
Even though new therapeutics means are still necessary in order to  improve myocardial perfusion, 
an early identification of patients at high risk for left ventricular remodelling may be crucial for a 
better patient care. A prompt aggressive pharmacologic therapy and an intensive clinical monitoring 
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are to be provided to those patients without an adequate microvascular perfusion, in order to 
improve their short and long-term outcome.  
 
Study limitations  
The present data are limited to a relatively small population and further studies are needed in order 
to confirm these results. However, we studied only patients submitted to primary PCI, thus making 
our population homogeneous. 
The primary end-point was echocardiographic left ventricular remodelling, which is a surrogate 
end-point. This was necessary since the incidence of clinical MACEs in selected patients who have 
been promptly reperfused is quite low and a large population or alternatively a long follow-up 
would have been required. 
The present study has been performed in a single Centre. Reproducibility of such angiographic data 
is still to be addressed. 
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CONCLUSIONS 
A prompt, successful reperfusion of the epicardial vessel during AMI may not be associated to an 
adequate perfusion also at the tissue level. Microvascular no reflow is significantly related to the 
development of left ventricular remodelling, which heavily affects patient prognosis. Both MBG or 
TMPG are simple and effective diagnostic tools able to provide an early prognostic stratification of 
a patient with AMI, immediately after primary PCI. 
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Table 1 Baseline clinical and echocardiographic characteristics 
 
Variables 
Overall 
(n=210) 
Rim 
(n=43 – 21.9%) 
No-Rim 
(n=153 – 78.1%) 
P Value 
Age, years 61.7±11.8 61.4±11.2 61.6±12.1 NS 
Body Surface, m2 1.87±0.14 1.85±0.15 1.87±0.14 NS 
Sex, male  163(77.6%) 35(81.4%) 118(77.1%) NS 
Family History 84(40.0%) 18(41.9%) 63(41.2%) NS 
Current Smoking 110(52.4%) 23(53.5%) 81(52.9%) NS 
Diabetes Mellitus 57(27.1%) 8(186%) 44(28.8%) NS 
Hypertension 95(45.2%) 21(48.8%) 65(42.5%) 0.09 
Dyslipidemia 107(50.9%) 18(41.9%) 86(56.2%) NS 
Periferical Artery Desease  10(4.8%) 1(2.3%) 8(5.2%) NS 
Previous Angina 68(32.4%) 13(30.2%) 50(32.7%) NS 
Previous IMA 33(15.7%) 5(11.6%) 27(17.6%) NS 
Killip Grade 
- 1 
- 2 
- 3 
- 4 
1.43±0.84 
154(73.7%) 
33(15.8%) 
9(4.3%) 
13(6.2%) 
1.63±1.05 
29(67.4%) 
6(14.0%) 
3(7.0%) 
5(11.6%) 
1.26±0.58 
122(79.6%) 
23(15.1%) 
5(3.3%) 
3(2.0%) 
0.025 
 
F-ratio: 3.23 
p: 0.024 
 
Killip >1 55(26.3%) 14(32.6%) 31(20.4%) 0.09 
Killip 3-4 22 (10.5%) 8(18.6%) 8(5.3%) 0.009 
ASA   
Clopidogrel  
Ticlopidina 
197(98.8%)  
160(76.2%) 
39(18.6%) 
39(90.7%) 
27(62.8%) 
10(23.3%) 
148(96.7%) 
122(79.7%) 
28(18.3%) 
NS 
0.02 
NS 
IIbIIIa GP Inhibithors 142(67.6%) 30(69.8%) 101(66.0%) NS 
ACE inhibitors at discharge 
beta-blockers at discharge 
 
 
  
NS 
NS 
CPK tot - peak, U/L 
 
3327± 3405 
 
5072±4243 
 
2642±2748 
 
<0.001 
 
 
Reperfusion Time, min 219±96 229±92 208±94 0.07 
ST elevation Resolution >70% 
                                        >50% 
92(44%) 
149(71%) 
13(48.1%) 
19(70.4%) 
48(46.6%) 
76(73.8%) 
NS 
NS 
     
     
     
Left Ventricular EF, % 
 
42.8±8.8 
 
39.0±9.4 
 
44.6±7.9 
 
<0.001 
 
Left Ventricular EDV, ml 93.2±21.8 89.4±20.4 93.6±22.6 NS 
Left Ventricular EDVi, ml 49.9±11.8 48.8±11.1 49.9±12.2 NS 
Left Ventricular WMSI 
 
1.66±0.34 
 
1.74±0.34 
 
1.62±0.33 
 
0.02 
 
IMA Asynergic Size 0.359±0.172 0.392±0.165 0.342±0.169 0.04 
175 (83.3%) 
132 (62.8%) 
37 (86%) 
26 (60.4%) 
135 (88.2%) 
95 (62%) 
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Variables 
Overall 
(n=210) 
Rim 
(n=43 – 21.9%) 
No-Rim 
(n=153 – 78.1%) 
P Value 
IRA  
      Left Anterior Descending 
      Left Circumflex 
      Right 
 
116(56.0%) 
26(12.6%) 
65(31.4%) 
 
31(72.1%) 
2(4.7%) 
10(23.3%) 
 
79(52.7%) 
19(12.7%) 
52(34.7%) 
 
0.02 
0.10 
NS 
Multivessel  CAD  
Trivessel      CAD 
122(58.7%) 
50(24.1%) 
27(64.3%) 
11(26.2%) 
87(57.2%) 
34(22.4%) 
NS 
NS 
Initial TIMI flow grade 
     0 
     1 
     2   
     3 
0.76±1.10 
132(62.9%) 
39(18.6%) 
27(12.8%) 
10(4.7%) 
0.46±0.80 
30(69.8%) 
7(16.3%) 
5(11.6%) 
1(2.3%) 
0.88±1.15 
86(56.2%) 
26(17.0%) 
15(9.8%) 
26(17.0%) 
0.05 
   
F-ratio: 2.16 
p: 0.09 
 
Final TIMI flow grade 
     3 
     2 
     1 
2.92±0.33 
196(93.8%) 
10(4.3%) 
4(1.9%) 
2.78±0.46 
35(81.4%) 
7(16.3%) 
1(2.3%) 
2.98±0.11 
151(98.7%) 
2(1.3%) 
0(0%) 
<0.001 
 
   F-Ratio: 11.58 
p<0.001 
Final TIMI flow grade 3 196(93.8%) 35(81.4%) 151(98.7%) <0.001 
Corrected TFC, f/sec 27.7±9.6 31.7±12.1 26.5±8.7 0.008 
cTFC <40 f/sec 
          <25 f/sec 
          <23 f/sec 
183(91.0%) 
92(45.8%) 
59(29.4%) 
32(80.0%) 
14(35.0%) 
10(25.0%) 
143(94.1%) 
76(50.0%) 
47(30.9%) 
0.01 
0.06 
NS 
Myocardial Blush Grade  
    MBG3 
    MBG2 
    MBG1     
    MBG0 
2.13±0.90 
87(41.6%) 
74(35.4%) 
36(17.2%) 
12(5.8%) 
1.56±0.96 
9(20.9%) 
11(25.6%) 
18(41.9%) 
5(11.6%) 
2.35±0.74 
74(48.4%) 
61(39.9%) 
15(9.7%) 
3(2.0%) 
<0.001               
 
F-Ratio: 14.4 
p<0.001 
 
MBG 0-1 48(23.0%) 23(53.5%) 18(11.8%) <.0001 
TIMI Myocardial Perfusion Grade  
    TMPG3 
    TMPG2 
    TMPG1     
    TMPG0 
2.08±0.88 
78(37.3%) 
83(39.2%) 
37(17.7%) 
12(5.8%) 
1.58±0.98 
9(20.9%) 
13(30.2%) 
15(34.9%) 
6(14.0%) 
2.29±0.72 
67(43.8%) 
66(43.1%) 
18(11.8%) 
2(1.3%) 
<0.001 
 
F-ratio: 11.4 
P<0.001 
 
TMPG 0-1 49(23.5%) 21(48.8%) 20(13.1%) <.0001 
Filterwire  41(19.5%) 6(14.0%) 33(21.6%) NS 
Stent implantation 
    Direct Stenting 
    PCI+Stent 
    PCI 
178(92.2%) 
114(59.1%) 
64(33.2%) 
15(7.8%) 
34(89.5%) 
18(47.4%) 
16(42.1%) 
4(10.5%) 
133(93.0%) 
91(63.6%) 
42(29.4%) 
10(7.0%) 
NS 
0.07 
NS 
NS 
Filter with Abciximab 
Filter without Abciximab 
Abciximab without Filter 
26(12.4%) 
15(7.1%) 
116(55.2%) 
4(9.3%) 
2(4.7%) 
26(60.5%) 
20(13.1%) 
13(8.5%) 
81(52.9%) 
NS 
NS 
NS 
TABLE 2 – ANGIOGRAPHIC CHARACTERISTICS  AND PROCEDURAL FEATURES 
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Variables 
Overall 
(n=210) 
Rim 
(n=43 – 21.9%) 
No-Rim 
(n=153 – 78.1%) 
P Value 
Fup Left Ventricular EF, % 46.8±10.2 39.7±10.1 49.5±7.6 <0.001 
Fup Left Ventricular EDV, ml 99.2±28.9 122.6±29.4 94.0±23.0 <0.001 
Fup Left Ventricular EDVi, ml/m2 53.2±15.7 66.9±15.5 50.1±12.3 <0.001 
Fup Left Ventricular WMSI 1.47±0.39 1.78±0.43 1.39±0.33 <0.001 
dEF, % 4.0±6.1 0.7±7.8 4.9±5.3 <0.001 
dEDV, ml 7.6±18.5 33.2±17.6 0.4±10.7 <0.001 
dEDVi, ml/m2 4.0±10.1 18.0±9.1 0.1±5.9 <0.001 
dWMSI 0.17±0.25 0.03±0.27 -0.23±0.21 <0.001 
IntraPCI mortalità 2(1.0%) 0(0%) 0(0%) NS 
12-month mortality 14(6.7%) 1(2.3%) 1(0.7%) NS 
Major bleedings 8(3.8%) 3(7.0%) 3(2.0%) NS 
Recurrent IMA 14(6.7%) 5(11.6%) 9(5.9%) NS 
Recurrent Angina 14(6.7%) 4(9.3%) 10(6.5%) NS 
Repeated PCI or CABG 15(7.2%) 4(9.3%) 11(7.2%) NS 
Stroke or TIA 2 (1.0%) 1(2.1%) 1(0.6%) NS 
EPA 2(1.0%) 0(0%) 1(2.3%) NS 
Global MACE 47 (22.4%) 12(27.9%) 23(15.0%) 0.04 
dEF >5,% 86(43.9%) 10(23.3%) 76(49.7%) 0.001 
Recovery of  LV function 129(66.9%) 15(34.9%) 114(76.0%) <0.001 
TABLE 3 –SIX-MONTH ECHOCARDIOGRAPHIC DATA AND ONE-YEAR CLINICALOUTCOME 
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One-year MACE Six-months Remodelling 
Variables 
p Value 
Univariata 
OR 
CI 95% 
P Value 
Multivariata 
p Value 
Univariata 
OR 
CI 95% 
P Value 
Multivariata 
Killip Grade 0.001 2.73 [0.78-9.62]  0.025   
IRA LAD NS   0.02   
Final TIMI flow grade 0.06   <0.001 3.5[0.6-6.5]  
cTFC NS   0.008   
MBG 0-1 post PCI <0.001 4.54[1.15-18.25] 0.03 <0.001 4.75 [1.85-12.50] 0.001 
TMPG 0-1 post PCI 0.005 2.55[0.75-5.95]  <0.001   
EF vaseline 0.002   <0.001 1.15 [1.04-1.25] 0.048 
WMSI vaseline 0.002   0.02   
ST persistent elevation  NS   0.005 1.02[0.20-1.25]  
CPKtot peak 0.007 1.02[0.98-1.04]  <0.001 1.12 [1.01-1.20] 0.036 
CK-MB peak 0.05 1.01[0.99-1.03]  <0.001   
TpI peak 0.02   <0.001   
       
EXCLUDED       
 Killip 3-4    0.009   
Clopidogrel    0.02   
cTFC >40    0.01   
EF <40%    0.002   
WMSI >1.5    0.03   
TABLE 4 – MULTIVARIATE ANALYSIS OF FACTORS RELATED TO CLINICAL OUTCOME. 
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Fig. 2 The increase of LV end diastolic volume is higher in pts with low MBG 
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Fig. 3 The increase of LV end diastolic volume is higher in pts with low TMPG 
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Empirical Confidence Interval of AUC for Condition = RIM20 
 
 Empirical AUC's Lower 95.0% Upper 95.0% Prevalence 
 Estimate of Standard Confidence Confidence of 
Criterion AUC Error Limit Limit RIM20 Count 
MBG01 0.70862 0.04064 0.61964 0.77962 0.21939 196 
TMPG01 0.67883 0.04092 0.59035 0.75118 0.21939 196 
 
 
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
ROC Curve of RIM20
1-Specificity
S
e
n
s
it
iv
it
y
Criterions
MBG01
TMPG01
 
 
 
 
 
Binormal Confidence Interval of AUC for Condition = RIM20 
 
 Binormal AUC's Lower 95.0% Upper 95.0% Prevalence 
 Estimate of Standard Confidence Confidence of 
Criterion AUC Error Limit Limit RIM20 Count 
MBG01 0.75684 0.04583 0.65185 0.83336 0.21939 196 
TMPG01 0.72168 0.04766 0.61455 0.80267 0.21939 196 
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Fig. 1 ROC curve showing the optimal cut point between sensitivity and specificity for the prediction of LV remodeling 
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Empirical Area Under Curve Analysis for Condition = RIM20 
 
 Empirical AUC's Z-Value 1-Sided 2-Sided Prevalence 
 Estimate of Standard to Test Prob Prob of 
Criterion AUC Error AUC > 0.5 Level Level RIM20 Count 
MBG01 0.70862 0.04064 5.13 0.0000 0.0000 0.21939 196 
TMPG01 0.67883 0.04092 4.37 0.0000 0.0000 0.21939 196 
 
 
Binormal Area Under Curve Analysis for Condition = RIM20 
 
 Binormal AUC's Z-Value 1-Sided 2-Sided Prevalence 
 Estimate of Standard to Test Prob Prob of 
Criterion AUC Error AUC > 0.5 Level Level RIM20 Count 
MBG01 0.75684 0.04583 4.10 0.0000 0.0000 0.21939 196 
TMPG01 0.72168 0.04766 3.64 0.0001 0.0003 0.21939 196 
 
 
 
 
Predictive Value Section for RIM20 using the Empirical ROC Curve 
 
MBG01 
Cutoff   Likelihood Prev. = 0.22 Prev. = 0.10 
Value Sensitivity Specificity Ratio PPV NPV PPV NPV 
0.00 1.00000 0.00000 1.00000 0.21939 1.00000 0.10000 1.00000 
1.00 0.53488 0.88235 4.54651 0.56098 0.87097 0.33562 0.94467 
 
Predictive Value Section for RIM20 using the Empirical ROC Curve 
 
TMPG01 
Cutoff   Likelihood Prev. = 0.22 Prev. = 0.10 
Value Sensitivity Specificity Ratio PPV NPV PPV NPV 
0.00 1.00000 0.00000 1.00000 0.21939 1.00000 0.10000 1.00000 
1.00 0.48837 0.86928 3.73605 0.51220 0.85806 0.29334 0.93862 
 
Predictive Value Section for RIM20 using the Binormal ROC Curve 
 
MBG01 
Cutoff   Likelihood Prev. = 0.22 Prev. = 0.10 
Value Sensitivity Specificity Ratio PPV NPV PPV NPV 
0.00 0.85539 0.35795 1.33227 0.27243 0.89804 0.12894 0.95704 
1.00 0.17837 0.99683 56.26618 0.94052 0.81192 0.86210 0.91610 
 
Predictive Value Section for RIM20 using the Binormal ROC Curve 
 
TMPG01 
Cutoff   Likelihood Prev. = 0.22 Prev. = 0.10 
Value Sensitivity Specificity Ratio PPV NPV PPV NPV 
0.00 0.83287 0.34956 1.28047 0.26464 0.88155 0.12455 0.94956 
1.00 0.15587 0.99492 30.68231 0.89608 0.80746 0.77320 0.91385 
 
Notes: 
Sensitivity is the Pr(Positive Test|Condition Present). 
Specificity is the Pr(Negative Test|Condition Absent). 
Likelihood Ratio is the ratio Pr(Positive Test|Condition Present)/Pr(Positive Test|Condition Absent). 
Prev stands for the prevalence of the disease. The first value is from the data. The other was input. 
PPV or Positive Predictive Value is the Pr(Condition Present|Positive Test). 
NPV or Negative Predictive Value is the Pr(Condition Absent|Negative Test). 
 
